Pathophysiology of Prurigo Nodularis: Neuroimmune Dysregulation and the Role of Type 2 Inflammation
Open Access
- 30 August 2024
- journal article
- review article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (2) , 249-256
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With NemolizumabJAMA Dermatology, 2023
- Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a studyeClinicalMedicine, 2023
- Periostin Activation of Integrin Receptors on Sensory Neurons Induces Allergic ItchCell Reports, 2020
- The IL-4/IL-13 axis in skin fibrosis and scarring: mechanistic concepts and therapeutic targetsArchives of Dermatological Research, 2019
- Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trialJournal of the American Academy of Dermatology, 2019
- The Itch–Scratch Cycle: A Neuroimmune PerspectiveTrends in Immunology, 2018
- Ethnic differences and comorbidities of 909 prurigo nodularis patientsJournal of the American Academy of Dermatology, 2018
- Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic ItchCell, 2017
- The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in explorationEuropean journal of pain, 2015
- Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasiaArchives of Dermatological Research, 2002